Governments Spent at Least €93bn on COVID-19 Vaccines and Therapeutics During the Last 11 Months
According to analysis conducted by kENUP Foundation, the public sector has dedicated at least €93bn to COVID-19 vaccines and therapeutics in 2020. More than 95%, about €88.3bn, was spent on vaccine companies. Only 5% of public COVID-19 funds were spent on therapeutics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210110005098/en/
New figures from kENUP Foundation show extent of public investments in COVID-19 vaccines and therapeutics (Photo: stilistica.design)
Most of the funds, around €86.5bn, were used to conclude advance market commitments (AMCs). In return for the right to buy a specified number of vaccine doses in a given timeframe, governments finance part of the upfront costs faced by vaccines producers in the form of AMCs. Just 7% of funds were spent through preferred loans or conventional grants.
The data also shows the origin of the funding: 32% of funds directed towards vaccine producers come from the US, 24% from the EU, and a total of 13% from the governments of Japan and South Korea.
For vaccines, exceptionally, governments invested 71% or at least €63.1bn into Small and Medium Enterprises (SMEs) and MidCaps. Only 18% of funds went to big pharma, underlining the importance of SMEs in driving innovation.
Holm Keller, Chairman of kENUP Foundation said: “Public investments have been instrumental in supporting innovation in the fight against the coronavirus. To bridge the time until broad rollout of vaccines, further investment in therapeutics is especially important. In parallel, a dedicated public pandemic preparedness scheme that would make vaccines and therapeutics readily available at lower development costs for any kind of pandemic pathogen is needed”.
The figures are kENUP’s analysis of publicly available information. They do not include private sector investments. The data was correct as at January 10, 2021.
About kENUP Foundation:
kENUP Foundation is a non-profit public benefit foundation supporting research-based innovation in health industries for societal benefit. kENUP initiates public and private investment into innovations with the potential to improve the livelihood of every citizen. The development of such innovations is often hampered by failing markets. Through its work, kENUP aims to change that.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210110005098/en/
Contact information
Press contact:
Tobias Mac-Lean, maclean@kenup.eu, https://www.kenup.eu
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VeriSilicon Unveils Next-Generation High-Performance Vitality Architecture GPU IP Series19.12.2024 01:00:00 CET | Press Release
VeriSilicon (688521.SH) today announced the launch of its latest Vitality architecture Graphics Processing Unit (GPU) IP series, designed to deliver high-performance computing across a wide range of applications, including cloud gaming, AI PC, and both discrete and integrated graphics cards. VeriSilicon’s new generation Vitality GPU architecture delivers exceptional advancements in computational performance with scalability. It incorporates advanced features such as a configurable Tensor Core AI accelerator and a 32MB to 64MB Level 3 (L3) cache, offering both powerful processing power and superior energy efficiency. Additionally, the Vitality architecture supports up to 128 channels of cloud gaming per core, addressing the needs of high concurrency and high image quality cloud-based entertainment, while enabling large-scale desktop gaming and applications on Windows systems. With robust support for Microsoft DirectX 12 APIs and AI acceleration libraries, this architecture is ideally su
Brightcove Drives Global Customer Growth and Value Through Strategic Partnerships with Leading MarTech Solutions18.12.2024 17:09:00 CET | Press Release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, is sharing significant enhancements to its platform through strategic partnerships to enhance the video content creation, distribution and monetization process. As part of the goal to help customers build more cohesive, easy-to-deploy martech stacks, Brightcove has integrated capabilities from companies like Acquia that deliver additional benefits to customers. “As we build strategic partnerships with key providers, we continually look at ways to help our customers reach their business goals. With the right partners, we enable marketers to fully leverage their content and get the most value out of it,” said David Beck, Chief Operating Officer at Brightcove. “Integrating our partners’ strengths – like Acquia’s DAM capabilities – seamlessly into Brightcove’s platform makes it easier for our customers to capture, deploy, and measure video to deliver compelling content that drives engagement and business with
GC Aesthetics® Announces Decade-Long Clinical Evaluation of PERLE™ Breast Implants18.12.2024 16:56:00 CET | Press Release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce the initiation of a significant multi-center and prospective clinical study in Europe to evaluate, and confirm, the safety, effectiveness, and patient satisfaction associated with the innovative PERLE™ smooth opaque round breast implant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218630395/en/ GC Aesthetics' PERLE™ Breast Implant features a proprietary surface technology (BioQ™) and GCA’s industry-leading gel technology (Emunomic™ Breast Tissue Dynamic Gel). (Photo: Business Wire) This extensive study brings together leading surgeons from the NHS and private clinics in the UK, as well as from private practices across Europe, ensuring a robust and diverse dataset that addresses both cosmetic and reconstructive indications. “By generating high-quality clin
Andersen Global Expands Capabilities with Addition of Valora18.12.2024 15:30:00 CET | Press Release
Andersen Global continues to broaden its service offerings through a Collaboration Agreement with Valora, an independent firm specializing in providing custom solutions for both private and institutional clients globally. Valora operates with offices in Miami and Raleigh, along with a global presence in the Dominican Republic, U.K., and Cayman Islands. Founded in 2011 by Partner Luis de Leon, Valora offers a comprehensive range of services, including valuation, performance, accounting and administration, global entity management, fund services, and other tailored solutions. “Collaborating with Andersen is an excellent fit for both our clients and our team,” said Luis. “The synergies within our service offerings will enable us to deliver comprehensive, integrated solutions with ever-increasing global reach.” Global Chairman and CEO of Andersen Mark L. Vorsatz stated, “Valora’s team and culture, along with their practice focus, are well aligned with our organization as we continue to exp
Novotech Publishes Report on the Global COVID-19 Clinical Trial Landscape, Highlighting Key Trends, Therapeutic Advancements, and Challenges in Drug Development18.12.2024 14:05:00 CET | Press Release
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released an in-depth report "COVID-19: Global Clinical Trial Landscape 2024." This report delivers a robust analysis of ongoing and completed COVID-19 clinical trials, therapeutic strategies, and funding trends, offering essential insights for researchers and biotech leaders in the evolving COVID-19 research landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218899045/en/ The COVID-19 pandemic has led to significant advancements in clinical research and therapeutic innovation. Novotech’s report offers an authoritative analysis of global trial distribution, patient recruitment trends, and emerging therapeutic strategies, drawing on over 5,000 clinical trials conducted since 2019 across Asia-Pacific, North America, Europe, and beyond
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom